US20040126430A1 - Compositions and kits for the removal of irritating compounds from bodily surfaces - Google Patents

Compositions and kits for the removal of irritating compounds from bodily surfaces Download PDF

Info

Publication number
US20040126430A1
US20040126430A1 US10/655,911 US65591103A US2004126430A1 US 20040126430 A1 US20040126430 A1 US 20040126430A1 US 65591103 A US65591103 A US 65591103A US 2004126430 A1 US2004126430 A1 US 2004126430A1
Authority
US
United States
Prior art keywords
composition
percent
capsaicin
kit
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/655,911
Other languages
English (en)
Inventor
Arturo Angel
Larry Litle
Keith Bley
Allan Wilcox
Gene Jamieson
Naweed Muhammad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/655,911 priority Critical patent/US20040126430A1/en
Priority to US10/810,185 priority patent/US20040180081A1/en
Assigned to NEUROGESX, INC. reassignment NEUROGESX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DOW PHARMACEUTICAL SCIENCES
Assigned to NEUROGESX, INC. reassignment NEUROGESX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WILCOX, ALLAN L.
Assigned to DOW PHARMACEUTICAL SCIENCES reassignment DOW PHARMACEUTICAL SCIENCES ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANGEL, ARTURO J., LITLE, LARRY W.
Publication of US20040126430A1 publication Critical patent/US20040126430A1/en
Priority to US11/435,188 priority patent/US20060204564A1/en
Priority to US11/435,187 priority patent/US20060204563A1/en
Assigned to NEUROGESX, INC. reassignment NEUROGESX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MUHAMMAD, NAWEED, BLEY, KEITH R., JAMIESON, GENE C., ANGEL, ARTURO J., LITLE, LARRY W., WILCOX, ALLAN L.
Priority to US12/830,997 priority patent/US8263059B2/en
Priority to US13/596,773 priority patent/US8889113B2/en
Priority to US14/542,041 priority patent/US9549893B2/en
Priority to US15/377,804 priority patent/US10463598B2/en
Assigned to ACORDA THERAPEUTICS, INC. reassignment ACORDA THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NEUROGESX, INC.
Priority to US16/581,102 priority patent/US10869827B2/en
Priority to US17/098,131 priority patent/US11534388B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/88—Two- or multipart kits

Definitions

  • kits, compositions, and methods for the removal of harmful or irritating substances from bodily surfaces in particular to kits containing a composition containing capsaicin or a capsaicin analog and a capsaicin-cleansing composition.
  • kits and compositions find application in medicine and animal health.
  • capsaicin is a constituent of pepper sprays, and capsaicin and its analogs are used in topical form for pain relief. Even at low concentrations (e.g., 0.075% by weight) capsaicin preparations can cause burning pain and hyperalgesia. This is the effect sought in pepper sprays, and is a side effect of therapeutic treatments of pain.
  • capsaicin concentrations used for the treatment of some intractable pain conditions the initial pain accompanying application of capsaicin is treated by anesthesia (see, e.g., U.S. Pat. Nos. 6,248,788 and 6,239,180).
  • One aspect of the invention provides a kit that includes a first device or composition containing capsaicin or a capsaicin analog; and a second device or composition containing a substance in which capsaicin is soluble, wherein the first and second devices or compositions are separately packaged.
  • the second composition is a composition in which capsaicin has a solubility of at least about 10 percent w/w.
  • the second composition is a composition in which capsaicin has a solubility of at least about 20 percent w/w.
  • the second composition is a composition in which capsaicin has a solubility of at least about 25 percent w/w.
  • the first composition of the kit may include capsaicin or a capsaicin analog in an amount sufficient to treat a capsaicin-responsive condition (e.g., a therapeutically effective amount), for example, a concentration between about 0.001 to about 60 percent w/w, e.g., about 0.001 to about 1 percent w/w, or about 0.1 to about 15 percent w/w or about 1 to about 10 percent w/w; for example, about 5 to about 10 percent w/w.
  • a capsaicin analog in an amount sufficient to treat a capsaicin-responsive condition (e.g., a therapeutically effective amount), for example, a concentration between about 0.001 to about 60 percent w/w, e.g., about 0.001 to about 1 percent w/w, or about 0.1 to about 15 percent w/w or about 1 to about 10 percent w/w; for example, about 5 to about 10 percent w/w.
  • the capsaicin or capsaicin analog is contained in a spray, lotion, emulsion, liniment, or gel. In other embodiments, the capsaicin or capsaicin analog is contained in a transdermal patch. In one such embodiment, the capsaicin or capsaicin analog is present in the transdermal patch at an amount of about 0.64 mg/cm 2 . In some embodiments of this aspect of the invention, the second composition of the kit contains polyethylene glycol and a polyacrylate thickening polymer.
  • the second composition of the kit contains about 60 to about 99 percent w/w polyethylene glycol (PEG); about 0.1 to about 4.0 percent w/w polyacrylate thickening agent; and the balance water; wherein the composition is at a pH between about 6.0 and about 8.0. In some embodiments, the second composition of the kit contains about 84 to about 94 percent w/w polyethylene glycol; about 0.1 to about 2 percent w/w polyacrylate thickening agent; and the balance water; wherein the composition is at a pH of about 7.0 to 7.5.
  • PEG polyethylene glycol
  • the balance water wherein the composition is at a pH between about 6.0 and about 8.0.
  • the second composition of the kit contains about 84 to about 94 percent w/w polyethylene glycol; about 0.1 to about 2 percent w/w polyacrylate thickening agent; and the balance water; wherein the composition is at a pH of about 7.0 to 7.5.
  • the second composition of the kit may contain, in addition to PEG and a polyacrylate thickener, about 0.005 to about 0.05 percent w/w butylated hydroxyanisole; and about 0.05 to about 0.5 percent w/w EDTA/EDTA salts.
  • the kit includes a third composition comprising an anesthetic.
  • Kits of the invention may also include instructions for use of the capsaicin composition and the cleansing composition.
  • the invention provides a kit comprising a transdermal patch comprising capsaicin and a capsaicin cleansing gel.
  • the kit may also provide an anesthetic.
  • the transdermal patch contains capsaicin at an amount of about 0.64 mg/cm 2 ; a cleansing gel containing about 84 to about 94 percent w/w polyethylene glycol, about 0.1 to about 2 percent w/w polyacrylate thickening agent, about 0.005 to about 0.05 percent w/w butylated hydroxyanisole, about 0.05 to about 0.5 percent w/w EDTA/EDTA salts, and the balance water; wherein the second composition is at a pH of about 7.0 to 7.7; and a composition comprising an anesthetic.
  • This embodiment may further contain instructions for use.
  • the present invention provides a composition for cleansing a bodily surface.
  • the invention provides composition in which capsaicin has a solubility of at least about 10% w/w, or at least about 20% w/w, or at least about 25% w/w.
  • Some embodiments of compositions provided by the invention include a component in which capsaicin is soluble, e.g., a component in which capsaicin is soluble to greater than about 10% w/w, greater than about 20% w/w, or greater than about 25% w/w, and a thickening agent.
  • a composition of the invention contains about 60 to about 99 percent w/w polyethylene glycol (PEG, e.g., PEG 300).
  • a composition of the invention contains about 60 to about 99 percent w/w polyethylene glycol (PEG, e.g., PEG 300), about 0.1 to about 4 percent w/w thickening agent, and the balance water; wherein the composition is at a pH between about 6.0 and about 8.0.
  • the thickening agent can be a polyacrylate.
  • the composition includes about 84 to about 94 percent w/w polyethylene glycol (PEG, e.g., PEG 300); about 0.1 to about 2 percent w/w polyacrylate thickening agent; and the balance water; wherein the composition is at a pH between about 7.0 and about 7.7.
  • the composition includes about 88 to about 92 percent w/w polyethylene glycol (PEG, e.g., PEG 300); about 0.1 to about 2 percent w/w polyacrylate thickening agent; and the balance water; wherein the composition is at a pH between about 7.0 and about 7.7.
  • the composition includes about 90 percent w/w polyethylene glycol (PEG, e.g., PEG 300); about 0.1 to about 2 percent w/w polyacrylate thickening agent; and the balance water; wherein the composition is at a pH between about 7.0 and about 7.7.
  • the composition includes about 84 to about 94 percent w/w polyethylene glycol (PEG, e.g., PEG 300); about 0.3 to about 1.5 percent w/w polyacrylate thickening agent; and the balance water; wherein the composition is at a pH between about 7.0 and about 7.7.
  • the composition includes about 84 to about 94 percent w/w polyethylene glycol (PEG, e.g., PEG 300); about 1.0 percent w/w polyacrylate thickening agent; and the balance water; wherein the composition is at a pH between about 7.0 and about 7.7.
  • the polyethylene glycol comprises PEG 200 or PEG 300.
  • compositions of the invention may also contain, in addition to PEG and a thickening agent, stabilizer(s).
  • stabilizers of the invention include about 0.005 to about 0.05 percent w/w butylated hydroxyanisole; and about 0.05 to about 0.5 percent w/w EDTA/EDTA salts.
  • Some embodiments that include stabilizers may include about 87 to about 91 percent w/w polyethylene glycol; about 0.3 to about 1.5 percent w/w polyacrylate thickening agent; about 0.01 to about 0.03 percent w/w butylated hydroxyanisole; about 0.02 to about 0.2 percent w/w EDTA/EDTA salts; and the balance water; wherein the composition is at a pH of about 7.0 to about 7.7.
  • a further embodiment includes about 89.08 percent w/w PEG 300; about 1.0 percent w/w polyacrylate thickening agent; about 0.02 percent w/w butylated hydroxyanisole; about 0.1 percent w/w EDTA/EDTA salts; and the balance water; wherein the composition is at a pH of about 7.5.
  • the invention includes an article of manufacture for cleansing a bodily surface including (a) a composition containing about 84 to about 94 percent w/w polyethylene glycol (PEG); about 0.1 to about 2.0 percent w/w polyacrylate thickening agent; and the balance water; wherein the composition is at a pH between about 7.0 and about 7.7; and (b) a container suitable for dispensing the composition of (a); where either the container is labeled with instructions for the use of the composition of (a), or the article of manufacture includes separate instructions for the use of the composition of (a).
  • PEG polyethylene glycol
  • the article of manufacture includes separate instructions for the use of the composition of (a).
  • Yet another aspect of the invention includes a method for cleansing a bodily surface that has been contacted with an irritating or painful substance.
  • the method includes the steps of (a) applying to the bodily surface a composition in which capsaicin has a solubility of at least about 10% w/w, or at least about 20% w/w, or at least about 25% w/w.; and (b) removing the composition of step (a) from the bodily surface.
  • the method includes the steps of (a) applying to the bodily surface a composition that contains about 60 to about 99 percent w/w polyethylene glycol (PEG, e.g., PEG 300); and (b) removing the composition of step (a) from the bodily surface.
  • PEG polyethylene glycol
  • the method includes the steps of (a) applying to the bodily surface a composition that contains about 60 to about 99 percent w/w polyethylene glycol (PEG, e.g., PEG 300), about 0.1 to about 4 percent w/w thickening agent, and the balance water; wherein the composition is at a pH between about 6.0 and about 8.0.; and (b) removing the composition of step (a) from the bodily surface.
  • PEG polyethylene glycol
  • the method includes the steps of (a) applying to the bodily surface a composition containing about 80 to about 99 percent w/w polyethylene glycol, about 0.1 to about 2 percent w/w polyacrylate thickening agent and the balance water; wherein the composition is at a pH of about 7.0 to about 7.7; and (b) removing the composition of step (a) from the bodily surface.
  • the method includes the steps of (a) applying to the bodily surface a composition containing about 87 to about 91 percent w/w polyethylene glycol, about 0.3 to about 1.5 percent w/w polyacrylate thickening agent, about 0.01 to about 0.03 percent w/w butylated hydroxyanisole, about 0.02 to about 0.2 percent w/w EDTA/EDTA salts and the balance water; wherein the composition is at a pH of about 7.0 to about 7.7; and (b) removing the composition of step (a) from the bodily surface.
  • a further aspect of the invention includes a method for treating an individual suffering from a capsaicin-responsive condition.
  • the invention provides a method for treating pain in an individual, including the steps of (a) applying a composition containing capsaicin or a capsaicin analog to the painful area; and (b) cleansing bodily surfaces that have been exposed to capsaicin by applying to the bodily surfaces a composition comprising a component in which capsaicin has a solubility of greater than 10% w/w, or greater than 20% w/w, or greater than 25% w/w; and removing said composition from the area.
  • the capsaicin or capsaicin analog is present in the capsaicin-containing composition in a total concentration greater than about 5% by weight.
  • step (a) of the method includes affixing to the affected area a skin-adherent patch, the patch including a reservoir containing a therapeutic formulation whereby said formulation is provided to the surface of the skin, and where the formulation contains capsaicin or a capsaicin analog in a total concentration from greater than about 5% to 10% by weight of the formulation.
  • the method further includes, in addition to applying capsaicin or capsaicin analogs and removing the capsaicin or capsaicin analogs, administering an anesthetic to the individual in whom pain is to be treated, prior to the application of the capsaicin or capsaicin analog.
  • the anesthetic is administered in the form of an afferent nerve block.
  • FIG. 1 illustrates schematically the manufacturing process for a cleansing solution.
  • kits that contain a component containing capsaicin or a capsaicin analog, and another component for cleansing capsaicin or a capsaicin analog, and methods for their use.
  • the invention also provides compositions useful for cleansing skin and other bodily surfaces, e.g., eyes and mucous membranes, that have been exposed to painful or irritating compounds, and methods for their use.
  • kits that include a composition containing capsaicin or a capsaicin analog together with a capsaicin cleansing composition in which capsaicin or a capsaicin analog is soluble.
  • capsaicin or the capsaicin analog is soluble to at least about 10% w/w, at least about 20% w/w, or at least about 25% w/w in the capsaicin cleansing composition.
  • the kits may further include a composition containing an anesthetic, instructions, and other optional components.
  • the invention provides compositions for cleansing skin and other bodily surfaces that have been exposed to a painful or irritating substance, e.g., capsaicin or a capsaicin analog.
  • the invention provides compositions in which capsaicin is soluble, e.g., in which capsaicin has a high solubility, that are non-toxic, and that are easy to apply and to remove.
  • the compositions do not readily penetrate the skin.
  • the compositions contain polyethylene glycol, a polyacrylate thickening agent, and water, at a pH suitable for topical use.
  • the compositions may also contain preservatives such as an antioxidant and a chelating agent.
  • compositions may be applied to bodily surfaces exposed to capsaicin or other painful or irritating compounds, e.g., by a tissue impregnated with the composition, then wiped off the bodily surface, to neutralize the irritating effect of the compound, e.g., capsaicin, on the eyes, skin, fascia, and mucous membranes.
  • the invention provides methods for removing irritating or painful substances from bodily surfaces by applying the compositions of the invention to the bodily surface, then removing them.
  • the invention provides methods for treating a capsaicin-responsive condition by applying capsaicin or a capsaicin analog to a bodily surface, then removing excess capsaicin or capsaicin analog.
  • the capsaicin-responsive condition is pain.
  • compositions provided herein include a first component in which capsaicin and its analogs are soluble, e.g., have high solubility.
  • the compositions include a second component that acts as a thickening agent, and water.
  • the pH is modified by a suitable pH modifier to a range appropriate for application to bodily surfaces, i.e., non-harmful and non-irritating pH.
  • the composition also includes stabilizers and/or other components.
  • the composition contains polyethylene glycol at high concentration and CARBOPOL 1382TM or similar carbomer or thickening agent, optionally including BHA and EDTA/EDTA salts.
  • the compositions contain polyethylene glycol, a polyacrylate thickener, and water, and are substantially free of other components.
  • the cleansing composition is substantially free of surfactant and/or particulates.
  • substantially free is meant that no surfactant and/or particulate is added to the composition, and any such components are present, if at all, only as trace impurities.
  • compositions of the invention may also be used for removal of other agents from bodily surfaces, e.g., toxins (e.g., pesticides, animal toxins), household chemicals (e.g., paint, varnish), and the like.
  • toxins e.g., pesticides, animal toxins
  • household chemicals e.g., paint, varnish
  • components of the cleansing solution typically do not penetrate the stratum corneum.
  • various aspects of the compositions will be described in greater detail.
  • compositions that can be applied to a bodily surface that has been exposed to an irritating or painful substance. These compositions may be described herein as “cleansing compositions” and, when the irritating or painful substance is capsaicin, “capsaicin-cleansing compositions.” As used herein, a composition “cleanses” a bodily surface of a painful or irritating substance, or is a “cleansing composition,” if, when the composition is applied to a bodily surface that has been exposed to a painful or irritating substance, then removed from the bodily surface, a substantial portion of the painful or irritating substance is also removed from the bodily surface.
  • compositions may cleanse a bodily surface when, on application to the exposed bodily surface, the composition acts to dissolve or mix with the irritating or painful substance without significantly penetrating the skin or other bodily surface, and can then be removed from the bodily surface, thereby removing a substantial portion of the painful or irritating substance.
  • the invention comprises compositions containing a component in which capsaicin or an analog of capsaicin is soluble; in some embodiments, the component is one in which capsaicin has a high solubility (i.e., greater than 10% w/w, or greater than 20% w/w, greater than 25% w/w).
  • Nonlimiting examples of substances in which capsaicin or its analogs may have a high solubility include lower monovalent alcohols (e.g., C 1 -C 4 ) and low molecular weight glycols and polyols, including propylene glycol, polyethylene glycol (e.g., 200-600 g/mole), polypropylene glycol (e.g., 425-2025 g/mole), glycerol, butylene glycol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, isopropanol, butanediol, ether propanol, ethoxylated ethers, propoxylated ethers and combinations thereof.
  • lower monovalent alcohols e.g., C 1 -C 4
  • low molecular weight glycols and polyols including propylene glycol, polyethylene glycol (e.g., 200-600 g/mole), polypropy
  • the component in which capsaicin has a high solubility is polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • Polyethylene glycol is an addition polymer of ethylene oxide and water, represented by the formula:
  • n represents the average number of oxyethylene groups.
  • PEGs and derivatives thereof the choice of PEG, PEGs, or their derivatives to be used in the lotions of the invention is mainly driven by considerations of viscosity; the desired viscosity depends on the type of lotion, gel, cream, liniment, or spray to be formulated (see section on viscosity).
  • suitable PEG's useful in embodiments of the invention include, for example, PEG 200-600.
  • PEG 300 is used.
  • Other PEGs may be used in embodiments of the invention. Non-limiting examples include PEG 200 and PEG 400.
  • PEG may be used that is substantially free of ethanol and/or methanol.
  • PEG e.g., PEG 300
  • PEG 300 may be provided in the compositions at a concentration of, e.g., about 60 to about 99.9 percent w/w, or about 80 to about 95 percent w/w, or about 84 to about 94 percent w/w, or about 87 to about 91 percent w/w, or about 89 percent w/w.
  • Suitable thickeners for use in the compositions of the present invention include crosslinked polyacrylate polymers, carboxylic acid polymers, polyacrylamide polymers, and mixtures thereof.
  • Exemplary thickeners are polymeric thickening agents including acrylic acid/ethyl acrylate copolymers and the carboxyvinyl polymers sold by the B. F. Goodrich Company under the trade mark of CARBOPOL resins. Such resins are described in, e.g., U.S. Pat. Nos. 5,288,814 and 5,468,814, and in Amjad et al., Carbomer Resins: Past, Present and Future Cosmetics & Toiletries 107 (1992), pp 81-85.
  • These resins consist essentially of a colloidally water-soluble polyalkenyl polyether crosslinked polymer of acrylic acid crosslinked with from 0.75% to 2.00% of a crosslinking agent such as for example polyallyl sucrose or polyallyl pentaerythritol.
  • a crosslinking agent such as for example polyallyl sucrose or polyallyl pentaerythritol.
  • examples include Carbopol 934, Carbopol 940, Carbopol 950, Carbopol 980, Carbopol 951 and Carbopol 981.
  • Carbopol 1382 is an exemplary CARBOPOL polymer that is used in some embodiments of the invention. See, e.g., U.S. Pat. No. 6,133,212. Other useful crosslinked nonionic polyacrylate polymers and crosslinked cationic polyacrylate polymers are described in U.S. Pat. Nos. 5,100,660; 4,849,484; 4,835,206; 4,628,078; 4,599,379; and EP 228,868, to Farrar et al, published Jul. 15, 1987.
  • thickeners may also be used in the invention, and include acacia, agar, alginic acid, aluminum monostearate, attapulgite (activated or colloidal activated), bentonite, purified bentonite, bentonite magma, carbomers 910, 934, 934P, 940, 941, and/or 1342, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carboxymethylcellulose sodium 12, carrageenan, microcrystalline cellulose, dextrin, gelatin, guar gum, hyaluronic acid, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, magnesium aluminum silicate, methylcellulose, pectin, polyethylene oxide, polyvinyl alcohol, povidone, propylene glycol alginate, silicon dioxide, colloidal silicon dioxide, sodium alginate, tragacanth, xanthan gum, aluminum silicates, and other thickeners known in the art; see, e.
  • the thickener is present in a concentration sufficient to provide proper viscosity to the composition for easy application to and removal from skin and other bodily surfaces.
  • the viscosity provided by the thickener, in combination with the polyethylene glycol, water, and optionally other components of the composition may be in the range from, e.g., a minimum of about 100, or about 300, or about 700, or about 2000, or about 4000 centipoise (cps) to a maximum of about 500, or about 700, or about 1000, or about 5000, or about 8000 cps.
  • the desired viscosity depends on the type of application.
  • the composition comprises a lotion to be applied by wiping and/or rubbing, which is preferably of a viscosity of about 4000 to about 8000 cps.
  • the composition comprises a less viscous preparation that may be applied by spraying, which is preferably of a viscosity of about 100 to about 1000 cps.
  • Other embodiments of intermediate viscosity between spray and lotion can also be useful.
  • the percentage of thickener in the composition depends on the type of PEG used (e.g., PEG 200, 300, or 400) and the percentage of PEG.
  • the quantity of carbomer to be used is determined by the desired viscosity which in turn depends on the intrinsic viscosity of carbomer.
  • a polyacrylate polymer for example CARBOPOL 1382TM comprises, e.g., about 0.1 to about 8 percent w/w, or about 0.1 to about 2 percent w/w, or about 0.1 to about 1.5 percent w/w, or about 0.3 to about 1.5 percent w/w, or about 1.0 percent w/w, of the composition.
  • compositions of the invention may optionally include one or more components that act as stabilizers.
  • Stabilizers useful in the compositions are materials that aid in ensuring a stable composition and/or prevent growth of bacteria. Measures of stability include, e.g., maintenance of viscosity over time, maintenance of pH over time, or maintenance of appearance, homogeneity, and/or color over time.
  • a stabilizer may be one or more of an antioxidant, a chelator, an antibacterial, or any other agent that acts to maintain desired characteristics of the composition over time.
  • Suitable stabilizers include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), disodium edetate, methylparaben, butylparaben, propylparaben, benzyl alcohol, sorbic acid, imidurea, thimerisal, propyl gallate, sodium phosphate (monobasic and/or dibasic) and citric acid.
  • BHA butylated hydroxyanisole
  • BHT butylated hydroxytoluene
  • disodium edetate disodium edetate
  • methylparaben butylparaben
  • propylparaben propylparaben
  • benzyl alcohol sorbic acid
  • imidurea thimerisal
  • propyl gallate sodium phosphate (monobasic and/or dibasic) and citric acid.
  • An example of an antioxidant for use in compositions of the invention is BHA, at about, e.g., 0.005 to about 0.1 percent w/w, or about 0.01 to about 0.05 percent w/w, or about 0.01 to 0.03 percent w/w, or about 0.02 percent w/w.
  • Suitable chelating agents include ethylene diaminetetraacetic acid (EDTA), as EDTA disodium, calcium disodium edetate, EDTA trisodium, EDTA tetrasodium, or EDTA dipotassium.
  • One or more chelating agents can optionally be included in the composition in amounts of about, e.g., 0.005 to about 1 percent w/w, or about 0.02 to about 0.2 percent w/w, or about 0.1 percent w/w.
  • a physiological buffer for example, sodium phosphate, either monobasic or dibasic, or both, may be included in the composition as a stabilizer that acts as a buffer to stabilize pH over time.
  • amounts may be, e.g., about 0.1 to about 1.5 percent w/w, or about 0.2 to about 1 percent w/w, or about 0.3 to about 0.7 percent w/w, or about 0.5 percent w/w.
  • amounts may be, e.g., about 0.2 to about 2 percent w/w, or about 0.4 to about 1.5 percent w/w, or about 0.6 to about 1.2 percent w/w, or about 0.8%.
  • compositions of the invention may optionally be added to compositions of the invention; see, e.g., U.S. Pat. Nos. 6,013,270 and 6,390,291.
  • the components of the composition are mixed with water to produce a composition of the desired viscosity. It is generally preferred to use water that has been purified by processes such as deionization or reverse osmosis, to improve the batch-to-batch formulation consistencies, by reducing or eliminating dissolved solids in the water supply.
  • the amount of water in the composition will vary, depending on the amounts of the other components of the composition.
  • the pH of the composition affects its potential for irritation of the bodily surface to which it is applied, as well as, in some embodiments, affecting the swelling of a thickener containing carboxyl groups by deprotonation of the carboxyl groups.
  • a pH modifier can be used to adjust the pH of the composition to a pH within a suitable range.
  • a pH modifier is a compound that will adjust the pH of a composition to a lower, e.g., more acidic pH value, or to a higher, e.g., more basic pH value.
  • Suitable pH modifiers include, for example, HCl, organic bases (such as triethanolamine) sodium hydroxide, potassium hydroxide, or ammonium hydroxide.
  • the pH modifier may be, for example, sodium hydroxide, to neutralize the polymer.
  • the composition may be at any pH that does not cause harm or irritation to the bodily surfaces to which the composition is applied in the intended manner and duration.
  • exemplary suitable pHs include, e.g., between about 6.0 to about 8.0, or between about 7.0 to about 7.7, or about 7.5.
  • compositions of the present invention may contain a wide range of additional, optional components. These depend on the intended use of the composition. For example, if the intended use includes cleansing the cul-de-sac of the eyes, the composition is preferably isotonic with respect to the fluids of the eye and sterile.
  • a solution that is isotonic to the eye is characterized by osmolalities of about 270 to about 330 mOsm/kg. Osmolality of the solution of the invention may be adjusted by means of chlorides and/or bicarbonates of sodium or potassium, sodium lactate, dextrose, and mannitol.
  • compositions for use in the eye may optionally include other components that are naturally-occurring elements of the tear fluid, such as proteins, enzymes, lipids and metabolites. See, e.g., U.S. Pat. No. 4,911,933. Because the composition is applied to the eye, the composition should be sterile.
  • compositions that may be added, depending on the intended use, include, e.g., surfactants, naphthol soap (available commercially as FELS-NAPTHATM), a cooling agent, a fragrance component, a skin soothing or skin healing agent, and/or polyethylene granules to assist the composition in reaching irregularities of the skin (used, e.g., to assist in removal of irritating substances from the skin, such as urushiols from poison oak, ivy, and sumac).
  • surfactants include, e.g., sodium lauryl sarcosinate, sodium lauryl sulfate, nonoxynol 9, and other long-chain surfactants.
  • cooling agents useful for the present invention include menthols, menthyl lactate, menthyl glycerol, menthyl salicylate, menthone glycerine acetal, alcohol, and borneols such as 1-menthol, d1-menthol, d-camphor,S d1-camphor, d-bomeol and d1-bomeol.
  • Plant extracts containing one or more of these compounds for example, peppermint oil, peppermint extract, Perilla frutescens Britton var. acuta Kudo extract, camphor tree extract and lavender extract, may also be used.
  • cooling agents examples include asymmetrical carbonates, thiocarbonates and urethanes, N-substituted carboxamides, ureas or phosphine oxides, as described in J. Cosmet. Chem., vol. 29, p. 185 (1978). These cooling agents may be used either singly or in any combination thereof.
  • the cooling component is preferably incorporated into the composition in a proportion of from about 0.001, 0.005, 0.02, 0.05, 0.1, 0.5, 2, 3, 4, 5, 6, 7, 8, 9, or 10% by weight, to about 0.005, 0.02, 0.05, 0.1, 0.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12 or 14% by weight. Cooling agents are further described in, e.g., U.S. Pat.
  • Fragrances are aromatic substances which can impart an aesthetically pleasing aroma to compositions of the invention.
  • Typical fragrances include aromatic materials extracted from botanical sources (e.g., rose petals, gardenia blossoms, jasmine flowers, etc.) which can be used alone or in any combination to create essential oils.
  • One or more fragrances can optionally be included in the composition in an amount ranging from about 0.001, 0.005, 0.02, 0.05, 0.1, 0.5, 2, 3, or 4% by weight to about 0.005, 0.02, 0.05, 0.1, 0.5, 2, 3, 4, or 5% by weight.
  • Fragrance agents are further described in, e.g., U.S. Pat. No. 6,428,772.
  • compositions of the present invention may further comprise a skin soothing or skin healing component.
  • Skin soothing or skin healing components suitable for use herein include, e.g., panthenoic acid derivatives (including, e.g., panthenol, dexpanthenol, ethyl panthenol), aloe vera, allantoin, bisabolol, and dipotassium glycyrrhizinate.
  • the skin soothing or skin healing agent may be added to the present composition in a proportion from about 0.05, 0.1, 0.5, 2, 3, 4, 5, 7,10,15, 20, or 25% by weight to about 0.1, 0.5, 2, 3, 4, 5, 7, 10, 15, 20, 25, or 30% by weight.
  • CTFA Cosmetic Ingredient Handbook Seventh Edition, 1997 and the Eighth Edition, 2000, describe a wide variety of other cosmetic and pharmaceutical ingredients commonly used in skin care compositions that are suitable for use in the compositions of the present invention.
  • these functional classes disclosed in this reference include: absorbents, abrasives, anticaking agents, antifoaming agents, binders, biological additives, buffering agents, bulking agents, chemical additives, colorants, fragrance components, humectants, opacifying agents, plasticizers, propellants, reducing agents, skin-conditioning agents (emollient, humectants, miscellaneous, and occlusive), skin protectants, solubilizing agents, and suspending agents (nonsurfactant).
  • Exemplary combinations of components for cleansing compositions include, for example, compositions containing polyethylene glycol, a thickening agent, and water, where the composition may contain, e.g., about 60 to about 99 percent w/w polyethylene glycol (PEG, e.g., PEG 300); about 0.1 to about 4 percent w/w polyacrylate thickening agent; and the balance water; where the composition is at a pH between about 6.0 and about 8.0.
  • PEG polyethylene glycol
  • a combination that may be used in the invention is a combination containing about 84 to about 94 percent w/w PEG (e.g., PEG 300); about 0.1 to about 2 percent w/w polyacrylate thickening agent; and the balance water; where the composition is at a pH of about 7.0 to about 7.7.
  • the latter composition may further contain stabilizer; for example, about 0.005 to about 0.05 percent w/w butylated hydroxyanisole; and about 0.05 to about 0.5 percent w/w EDTA/EDTA salts.
  • the composition may contain about 87 to about 91 percent w/w PEG (e.g., PEG 300); about 0.3 to about 1.5 percent w/w polyacrylate thickening agent; about 0.01 to about 0.03 percent w/w butylated hydroxyanisole; about 0.02 to about 0.2 percent w/w EDTA/EDTA salts; and about 9 to about 13 percent w/w water; where the composition is at a pH of about 7.0 to about 7.7.
  • PEG e.g., PEG 300
  • polyacrylate thickening agent about 0.01 to about 0.03 percent w/w butylated hydroxyanisole
  • about 0.02 to about 0.2 percent w/w EDTA/EDTA salts about 9 to about 13 percent w/w water
  • the composition may contain about 89.08 percent w/w PEG 300; about 1.0 percent w/w polyacrylate thickening agent; about 0.02 percent w/w butylated hydroxyanisole; about 0.1 percent w/w disodium edetate; and the balance water; where the composition is at a pH of about 7.5.
  • the composition is about 87 to about 91 percent w/w PEG (e.g., PEG 300); about 0.3 to about 1.5 percent w/w polyacrylate thickening agent; about 0.01 to about 0.03 percent w/w butylated hydroxyanisole; about 0.02 to about 0.2 percent w/w EDTA/EDTA salts; and about 9 to about 13 percent w/w water; where the composition is at a pH of about 7.0 to about 7.7.
  • PEG e.g., PEG 300
  • the composition may be provided in any suitable container known in the art or apparent to the ordinarily skilled artisan.
  • Exemplary containers for the composition include towels or towellettes in which the composition is impregnated or dispersed, or containers holding the composition and from which the composition may be dispensed.
  • Such containers may comprise elements for convenient dispensing of the composition, such as described in, e.g., U.S. Pat. No. 6,013,270.
  • the composition may be provided impregnated in a porous substrate (e.g., towellette), such as described in, e.g., U.S. Pat. No. 6,015,763.
  • the container may be further contained in suitable packaging.
  • the composition is provided in a container, and optionally further packaging, and a set of instructions for use of the composition to remove irritating substances, e.g., capsaicin, from the skin is also included.
  • the instructions may be in any form, and provided, e.g., as a separate insert or on a label that is affixed to the container or packaging.
  • Exemplary additional components include chemical-resistant disposal bags, applicators for applying the cleansing composition, towels or towellettes for the capsaicin cleansing lotion, diluent, gloves, eye protection, scissors, marking pens, and additional bodily surface-cleansing agents such as alcohol swabs.
  • the present invention provides a kit including a composition comprising capsaicin (or capsaicin analog) and a composition in which capsaicin (or capsaicin analog) is soluble to at least about 10% w/w, or at least about 20% w/w, or at least about 25% w/w.
  • a kit of the invention include a capsaicin cleansing composition described above.
  • a third composition comprising an anesthetic may also be provided.
  • the kits of the present invention may further comprise suitable packaging of the respective compositions, instructions, and/or other optional components as disclosed below.
  • kits provided herein comprise a composition containing capsaicin or a capsaicin analog.
  • Capsaicin and its analogs are used both as irritants (e.g., pepper sprays) and in preparations for the relief of pain. Capsaicin selectively modulates sensory nerve fibers in such a way as to activate, then desensitize, nociceptors in peripheral tissues. Analogs of capsaicin with physiological properties similar to capsaicin may also be used in the kits provided herein; exemplary analogs of capsaicin are nonivamide, capsaicin isomers, and dihydrocapsaicin, described in, e.g., Govindarajan and Sathyanrayana, Crit Rev Food Sci Nutr 29:435-474 (1991); U.S. Pats. Nos.
  • Kits of the invention may include a composition comprising capsaicin or a capsaicin analog in a wide variety of concentrations. These include, e.g., about 0.001 to about 60% by weight, for example, about 0.001 to about 1% by weight; or about 0.05% to about 15% by weight, or about 1% to about 10% by weight, or about 5% to about 10% by weight, or about 7.5% by weight.
  • the capsaicin or capsaicin analog may be present at, e.g., about 0.01 mg/cm 2 to about 1 mg/cm 2 , or about 0.1 to about 1 mg/cm 2 , or about 0.3 to about 0.9 mg/cm 2 , or about 0.64 mg/cm 2 .
  • the capsaicin or capsaicin analog composition of the kits includes a vehicle suitable for topical or dermal application, for example (but not limited to) those described in U.S. Pat. Nos. 6,239,180 and 6,248,788. These patents disclose high concentration (e.g., >5% w/w) capsaicin or capsaicin analog compositions (including dermal patches) for topical applications, wherein the capsaicin may be in a vehicle such as a lotion, e.g. velvachol (available from Galderma USA) and EUCERINTM.
  • a lotion e.g. velvachol (available from Galderma USA) and EUCERINTM.
  • the capsaicin is contained in a vehicle comprising a skin penetrating lotion or dispersed in a vehicle comprising a polymeric matrix, or mixed directly with a vehicle that also serves as adhesive for the patch.
  • a vehicle comprising a skin penetrating lotion or dispersed in a vehicle comprising a polymeric matrix
  • Other methods for the construction and uses of transdermal patches may be found in, e.g., Drug Delivery Systems Characteristics and Biomedical Application, R. L. Juiano, ed., Oxford University Press, N.Y. (1980); and Controlled Drug Delivery, Vol. I Basic Concepts, Stephen D. Bruck (1983).
  • capsaicin or capsaicin analog and vehicle may be further packaged in any suitable packaging for segregation from other components of the kit and to facilitate dispensing of the composition.
  • the cleansing composition of the kits may be a composition in which capsaicin is soluble to at least about 10% w/w, or at least about 20% w/w, or at least about 25% w/w; e.g., any of the capsaicin cleansing compositions described herein.
  • the composition may be provided in any suitable container, as described previously.
  • the container may comprise elements for convenient dispensing of the cleansing composition, such as described in, e.g., U.S. Pat. No. 6,013,270.
  • the cleansing composition may be provided impregnated in a porous substrate, such as described in, e.g., U.S. Pat. No. 6,015,763.
  • the container may be further packaged in any suitable packaging for segregation from other components of the kit and to facilitate dispensing of the cleansing composition.
  • kits of the invention may optionally further include an anesthetic composition. Burning pain and hyperalgesia to both heat and touch typically occur after applications of even the relatively low concentration capsaicin ointments known to the art. Such burning pain may be avoided by first administering an anesthetic, so as to cause regional anesthesia in the areas to be treated.
  • Exemplary regional anesthetic agents that may be used in the anesthetic compositions optionally included in the kits of the invention are sodium channel blockers. A variety of sodium channel blocking anesthetics are known and useful, such as lidocaine, tetracaine, bupivicaine and chloroprocaine.
  • the suitable anesthetic may be contained in a vehicle such as lotion or gel (see description for capsaicin compositions) or as a patch device (see description for capsaicin compositions).
  • a vehicle such as lotion or gel (see description for capsaicin compositions) or as a patch device (see description for capsaicin compositions).
  • Anesthetics for use with capsaicin compositions are further described in U.S. Pat. Nos. 6,239,180 and 6,248,788.
  • the anesthetic and vehicle may be further packaged in any suitable packaging for segregation from other components of the kit and to facilitate dispensing of the composition.
  • Kits of the invention may further include instructions for use of the cleansing composition. Instructions may be included as a separate insert and/or as part of the packaging or container, e.g., as a label affixed to a container or as writing or other communication integrated as part of a container. The instructions may inform the user of methods for application and/or removal of the cleansing composition, precautions and methods concerning handling of material contaminated with an irritating or painful substance, expected results, warnings concerning improper use, and the like.
  • Kits of the present invention may further contain components useful in the application and removal of capsaicin or capsaicin analogs.
  • additional components include chemical-resistant disposal bags, applicators, bodily surface-cleansing agents such as alcohol swabs, diluent, towels or towellettes for wiping excess cream prior to the use of the capsaicin cleansing lotion and for wiping cleansing lotion, gloves, scissors, marking pens and eye protection.
  • FIG. 1 One method for making some embodiments of the cleansing lotions provided by the present invention is shown in FIG. 1.
  • PEG, water, and (if used) stabilizers such as BHA and/or EDTA and/or sodium phosphate, are combined in a manufacturing vessel and mixed until dissolved.
  • the thickening agent e.g., CARBOPOL 1382
  • a pH modifier e.g., 10% sodium hydroxide solution
  • the invention also provides methods for using the compositions and kits of the invention.
  • the invention provides a method for cleansing a bodily surface that has been contacted with an irritating or painful substance (e.g., capsaicin or a capsaicin analog, or a urushiol).
  • Bodily surfaces to be treated may include skin, eyes, mucous membranes, hair, and, in the case of animals, fur (e.g., to cleanse an animal that has come into contact with an irritating, painful, or noxious substance).
  • the bodily surface is cleansed by applying to the bodily surface a cleansing composition containing polyethylene glycol, a thickening agent, and water, then removing the composition from the bodily surface.
  • the cleansing composition may contain, e.g., about 80 to about 99 percent w/w polyethylene glycol; about 0.1 to about 2 percent w/w polyacrylate thickening agent; and about 1 to about 20 percent w/w water; where the composition is at a pH of about 7.0 to about 7.7.
  • the cleansing composition may contain about 87 to about 91 percent w/w polyethylene glycol; about 0.3 to about 1.5 percent w/w polyacrylate thickening agent; about 0.01 to about 0.03 percent w/w butylated hydroxyanisole; about 0.02 to about 0.2 percent w/w EDTA/EDTA salts; and about 9 to about 13 percent w/w water; where the composition is at a pH of about 7.0 to about 7.7; then removing the composition from the bodily surface.
  • Methods of the invention also include methods for treating an individual suffering from a capsaicin-responsive condition with the kits of the invention.
  • capsaicin-responsive conditions include neuropathic pain (including pain associated with diabetic neuropathy, postherpetic neuralgia, HIV/AIDS, traumatic injury, complex regional pain syndrome, trigeminal neuralgia, erythromelalgia and phantom pain), pain produced by mixed nociceptive and/or neuropathic mixed etiologies (e.g., cancer, osteoarthritis, fibromyalgia and low back pain), inflammatory hyperalgesia, vulvar vestibulitis or vulvodynia, interstitial cystitis, neurogenic or overactive bladder, prostatic hyperplasia, rhinitis, rectal hypersensitivity, burning mouth syndrome, oral mucositis, herpes (or other viral infections), prostatic hypertrophy, dermatitis, pruritis, itch, tinnit
  • neuropathic pain
  • an “individual” is a vertebrate; e.g., a mammal; e.g., a human.
  • the condition is treated by applying a composition comprising capsaicin or a capsaicin analog (as described above) to the area affected by the condition, then cleansing the area with a cleansing composition of the invention.
  • the capsaicin may be administered in any number of ways, e.g., in a lotion, cream, emulsion, liniment, spray, transdermal patch, gel, or the like.
  • the method may further include administering an anesthetic prior to the application of the capsaicin-containing composition, for example administering an afferent nerve fiber blocking regional anesthetic to the affected area.
  • the composition comprising capsaicin or a capsaicin analog may be contained in a transdermal patch.
  • the capsaicin cleansing composition may be used to cleanse areas around the patch after it has been affixed as well as any areas inadvertently exposed to capsaicin; in addition the capsaicin cleansing composition may be used to cleanse the area to which the patch was affixed, after removal of said patch.
  • a tube containing 50 gm of cleansing gel may be applied to a site following removal of capsaicin patch, e.g., an 8% capsaicin patch.
  • the cleansing gel is left on the area for a period of time sufficient to allow capsaicin to be removed from the bodily surface to the gel, for example, for one minute, and then wiped off with dry gauze or dry paper towels. Upon removal from the treated area, all used gauze, paper towels or other materials placed in contact with the treated area are immediately disposed of in a plastic biohazard bag, which is then closed and sealed.
  • the patch includes a reservoir containing a therapeutic formulation where the formulation is provided to the surface of the skin, and where the formulation comprises capsaicin or a capsaicin analog in a total concentration from greater than about 5% by weight of the formulation. In some embodiments, the capsaicin concentration is less than or equal to about 5% by weight of the composition.
  • capsaicin has a high solubility in PEG 300, which also has low irritation potential and is compatible with a variety of excipients.
  • PEG 300 has the greatest capacity for capsaicin, with a capsaicin solubility of 27.5% w/w. 90% PEG 300 has a greater solubility for capsaicin than 80% PEG 300 (27.0% vs. 12.5%, respectively). Capsaicin is also quite soluble in PEG 200, at 27%.
  • formulations were prepared using various pH modifiers and with or without BHA and/or EDTA, or sodium phosphate, and their stabilities were followed over time at three different temperatures. Stability was assessed by evaluating appearance, pH, and viscosity. The formulations used are presented in Table 3. TABLE 3 Formulations tested for stability % (w/w) Component 43A 43B 44A 44B 45A 54A 54B PEG 300 89.2 79.2 89.2 88.85 89.1 89.18 89.08 CARBOPOL 1382 0.5 0.5 0.5 0.75 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Sodium Hydroxide 0.03 0.03 — 0.04 0.03 0.03 0.03 0.03 50% Trolamine Soln.
  • Stability data are presented in Table 4 (pH's are lower than the formulated pH's because the samples were diluted 1:9 with water). The method of preparation is shown in FIG. 1. TABLE 4 Stability data for various formulations Test Viscosity % Batch Storage From No.: Condition Time Appearance pH (1:9) cps Initial 790- 5° C.
  • This Example shows that several formulations are stable over time, especially those containing both BHA and EDTA, e.g., sample 790-54B.
  • capsaicin A stock solution of capsaicin, in methanol, containing 103.1 mg/100 mL capsaicin ((Lot F0010103) Formosa Laboratories, Taiwan) in a 100-mL volumetric flask, was prepared. The solution was clear and colorless. 10 mL each of four concentrations of capsaicin solutions 0.4 mg/mL, 0.3 mg/mL, 0.2 mg/mL and 0.1 mg/mL were prepared from above stock solution.
  • the dried coupon was smeared with 1 mL of cleansing gel which was removed after one minute with a single pre-washed swab (which was also used to apply cleansing gel).
  • the collected gel along with the swab was added to a pre-washed scintillation vial containing a small magnetic stirrer. 9 mL methanol was added and the sample was stirred for 10 minutes.
  • Three more samples were prepared in similar fashion using 0.4 mg/mL, 0.3 mg/mL and 0.2 mg/mL capsaicin solutions. TABLE 5 describes the percent capsaicin recovery from four samples containing different initial capsaicin amounts.
  • This example describes the preparation of cleansing gels containing menthol as a cooling agent.
  • Cleansing gel formulations containing 1% L-menthol were prepared by combining 1.20 g of L-menthol (Spetram RL 1492) with 118.8 g of cleansing gel, mixing it overnight and additionally for 1 hour in a steam bath.
  • the resulting formulation was a colorless gel with small amount of white solids, a characteristic odor of menthol, and a viscosity of 7,250 cps.
  • Cleansing gel formulations with 3% L-menthol were prepared by combining 3.61 g of L-menthol (Spetram RL 1492) with 116.41 g of cleansing gel, mixing it overnight and additionally for 1 hour in a steam bath.
  • the resulting formulation was a colorless gel with medium amount of white solids, a characteristic odor of menthol, and a viscosity of 6,500 cps.
  • Cleansing gel formulations with 10% L-menthol were prepared by combining 1.20 g of L-menthol (Spetram RL 1492) with 118.8 g of cleansing gel, mixing it overnight and additionally for 1 hour in a steam bath.
  • the resulting formulation was a colorless gel with white solids, a characteristic odor of menthol, and a viscosity of 4,750 cps.
  • This example describes the lack of skin penetration of polyethylene glycols that make up PEG 300.
  • PEG 300 is a polymer of ethylene glycol. The molecular weight of polymers is reported as an average of all constituting fractions. PEG has an average molecular weight of 300. PEG 300 was analyzed to detect and estimate polymer units with 5 to 8 monomer units the molecular weights of which constitute a range centered on 300 (i.e. PEG 239, PEG 283, PEG 327, and PEG 371). As expected these molecules were abundant in the cleansing compositions provided by the present invention, as determined by LC-MS, and were used as representative molecules in this Example.
  • the cleansing gel described in Example 4 was placed on human cadaver skin that was mounted on an O-ring and placed between the donor and receiver chambers of a Franz diffusion cell. The penetration of the four components across the skin was investigated over a three-hour period. These results were compared to those for caffeine, a reference compound for high permeation, and atenolol, a reference compound for low permeation. Table 6 provides the skin permeability coefficients (Papp) for the monitored components of the cleansing gel composition and the two reference compounds. Donor #1 was untreated skin. Donor #2 was skin treated with an 8% capsaicin composition for 60 minutes.
  • the Papp of each of the four main components of the cleansing gel was significantly lower than the low permeability reference, indicating that the permeability of skin to the polyethylene glycol components of the cleansing gel is exceptionally low, e.g., having a Papp of not greater than 1 ⁇ 10 ⁇ 6 , or 5 ⁇ 10 ⁇ 7 cm/hr.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Detergent Compositions (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Paints Or Removers (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
US10/655,911 2002-09-05 2003-09-05 Compositions and kits for the removal of irritating compounds from bodily surfaces Abandoned US20040126430A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
US10/655,911 US20040126430A1 (en) 2002-09-05 2003-09-05 Compositions and kits for the removal of irritating compounds from bodily surfaces
US10/810,185 US20040180081A1 (en) 2002-09-05 2004-03-26 Compositions and kits for the removal of irritating compounds from bodily surfaces
US11/435,188 US20060204564A1 (en) 2002-09-05 2006-05-15 Compositions and kits for the removal of irritating compounds from bodily surfaces
US11/435,187 US20060204563A1 (en) 2002-09-05 2006-05-15 Compositions and kits for the removal of irritating compounds from bodily surfaces
US12/830,997 US8263059B2 (en) 2002-09-05 2010-07-06 Compositions and kits for the removal of irritating compounds from bodily surfaces
US13/596,773 US8889113B2 (en) 2002-09-05 2012-08-28 Compositions and kits for the removal of irritating compounds from bodily surfaces
US14/542,041 US9549893B2 (en) 2002-09-05 2014-11-14 Compositions and kits for the removal of irritating compounds from bodily surfaces
US15/377,804 US10463598B2 (en) 2002-09-05 2016-12-13 Compositions and kits for the removal of irritating compounds from bodily surfaces
US16/581,102 US10869827B2 (en) 2002-09-05 2019-09-24 Compositions and kits for the removal of irritating compounds from bodily surfaces
US17/098,131 US11534388B2 (en) 2002-09-05 2020-11-13 Compositions and kits for the removal of irritating compounds from bodily surfaces

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40875102P 2002-09-05 2002-09-05
US41061602P 2002-09-13 2002-09-13
US10/655,911 US20040126430A1 (en) 2002-09-05 2003-09-05 Compositions and kits for the removal of irritating compounds from bodily surfaces

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US10/810,185 Continuation US20040180081A1 (en) 2002-09-05 2004-03-26 Compositions and kits for the removal of irritating compounds from bodily surfaces
US11/435,188 Division US20060204564A1 (en) 2002-09-05 2006-05-15 Compositions and kits for the removal of irritating compounds from bodily surfaces
US11/435,187 Division US20060204563A1 (en) 2002-09-05 2006-05-15 Compositions and kits for the removal of irritating compounds from bodily surfaces
US12/830,997 Continuation US8263059B2 (en) 2002-09-05 2010-07-06 Compositions and kits for the removal of irritating compounds from bodily surfaces
US12/830,997 Continuation-In-Part US8263059B2 (en) 2002-09-05 2010-07-06 Compositions and kits for the removal of irritating compounds from bodily surfaces

Publications (1)

Publication Number Publication Date
US20040126430A1 true US20040126430A1 (en) 2004-07-01

Family

ID=31981609

Family Applications (10)

Application Number Title Priority Date Filing Date
US10/655,911 Abandoned US20040126430A1 (en) 2002-09-05 2003-09-05 Compositions and kits for the removal of irritating compounds from bodily surfaces
US10/810,185 Abandoned US20040180081A1 (en) 2002-09-05 2004-03-26 Compositions and kits for the removal of irritating compounds from bodily surfaces
US11/435,188 Abandoned US20060204564A1 (en) 2002-09-05 2006-05-15 Compositions and kits for the removal of irritating compounds from bodily surfaces
US11/435,187 Abandoned US20060204563A1 (en) 2002-09-05 2006-05-15 Compositions and kits for the removal of irritating compounds from bodily surfaces
US12/830,997 Expired - Fee Related US8263059B2 (en) 2002-09-05 2010-07-06 Compositions and kits for the removal of irritating compounds from bodily surfaces
US13/596,773 Expired - Lifetime US8889113B2 (en) 2002-09-05 2012-08-28 Compositions and kits for the removal of irritating compounds from bodily surfaces
US14/542,041 Expired - Lifetime US9549893B2 (en) 2002-09-05 2014-11-14 Compositions and kits for the removal of irritating compounds from bodily surfaces
US15/377,804 Expired - Lifetime US10463598B2 (en) 2002-09-05 2016-12-13 Compositions and kits for the removal of irritating compounds from bodily surfaces
US16/581,102 Expired - Lifetime US10869827B2 (en) 2002-09-05 2019-09-24 Compositions and kits for the removal of irritating compounds from bodily surfaces
US17/098,131 Expired - Lifetime US11534388B2 (en) 2002-09-05 2020-11-13 Compositions and kits for the removal of irritating compounds from bodily surfaces

Family Applications After (9)

Application Number Title Priority Date Filing Date
US10/810,185 Abandoned US20040180081A1 (en) 2002-09-05 2004-03-26 Compositions and kits for the removal of irritating compounds from bodily surfaces
US11/435,188 Abandoned US20060204564A1 (en) 2002-09-05 2006-05-15 Compositions and kits for the removal of irritating compounds from bodily surfaces
US11/435,187 Abandoned US20060204563A1 (en) 2002-09-05 2006-05-15 Compositions and kits for the removal of irritating compounds from bodily surfaces
US12/830,997 Expired - Fee Related US8263059B2 (en) 2002-09-05 2010-07-06 Compositions and kits for the removal of irritating compounds from bodily surfaces
US13/596,773 Expired - Lifetime US8889113B2 (en) 2002-09-05 2012-08-28 Compositions and kits for the removal of irritating compounds from bodily surfaces
US14/542,041 Expired - Lifetime US9549893B2 (en) 2002-09-05 2014-11-14 Compositions and kits for the removal of irritating compounds from bodily surfaces
US15/377,804 Expired - Lifetime US10463598B2 (en) 2002-09-05 2016-12-13 Compositions and kits for the removal of irritating compounds from bodily surfaces
US16/581,102 Expired - Lifetime US10869827B2 (en) 2002-09-05 2019-09-24 Compositions and kits for the removal of irritating compounds from bodily surfaces
US17/098,131 Expired - Lifetime US11534388B2 (en) 2002-09-05 2020-11-13 Compositions and kits for the removal of irritating compounds from bodily surfaces

Country Status (15)

Country Link
US (10) US20040126430A1 (US07794751-20100914-C00003.png)
EP (1) EP1539124B1 (US07794751-20100914-C00003.png)
JP (2) JP4279254B2 (US07794751-20100914-C00003.png)
AU (1) AU2003270325A1 (US07794751-20100914-C00003.png)
CA (2) CA2903031C (US07794751-20100914-C00003.png)
CY (1) CY1120926T1 (US07794751-20100914-C00003.png)
DK (1) DK1539124T3 (US07794751-20100914-C00003.png)
EA (1) EA012367B1 (US07794751-20100914-C00003.png)
ES (1) ES2687970T3 (US07794751-20100914-C00003.png)
HU (1) HUE042241T2 (US07794751-20100914-C00003.png)
LT (1) LT1539124T (US07794751-20100914-C00003.png)
MX (1) MXPA05002440A (US07794751-20100914-C00003.png)
PT (1) PT1539124T (US07794751-20100914-C00003.png)
SI (1) SI1539124T1 (US07794751-20100914-C00003.png)
WO (1) WO2004021990A2 (US07794751-20100914-C00003.png)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060100287A1 (en) * 2004-11-05 2006-05-11 Kenji Okajima Insulin-like growth factor-1 secretagogue
US20060148903A1 (en) * 2004-11-24 2006-07-06 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
US20060204564A1 (en) * 2002-09-05 2006-09-14 Angel Arturo J Compositions and kits for the removal of irritating compounds from bodily surfaces
US20060233901A1 (en) * 2005-04-01 2006-10-19 Jamieson Gene C Oils of capsaicinoids and methods of making and using the same
US20060269628A1 (en) * 2002-12-18 2006-11-30 Algorx Infiltration of capsaicin into surgical sites and open wounds
US20070036876A1 (en) * 2002-12-18 2007-02-15 Algorx Injectable capsaicin
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
US20070224155A1 (en) * 2006-03-21 2007-09-27 Access Business Group International, Llc Cleansing compositions and methods of reducing skin irritation
US20070293703A1 (en) * 2003-04-08 2007-12-20 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
US20080064711A1 (en) * 2002-11-21 2008-03-13 J.P.M.E.D. Ltd. Composition for treating oral cavity and Mucousal infections
WO2008103180A1 (en) 2007-02-23 2008-08-28 Hill's Pet Nutrition, Inc. Compositions and methods for preventing or treating obesity in animals
US20100234470A1 (en) * 2008-09-12 2010-09-16 Anesiva, Inc. Instillation Administration of Capsaicinoids for the Treatment of Pain
US20180296497A1 (en) * 2014-10-31 2018-10-18 Avent, Inc. Method and Articles for Inhibiting Bladder Contractions

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2907503A1 (en) 2003-04-10 2015-08-19 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
DE102004009904A1 (de) * 2004-02-26 2005-09-22 Grünenthal GmbH Kit aus einem gegebenenfalls wirkstoffhaltigen Pflaster und einem Hautirritationen verhindernden Mittel
JP2006151971A (ja) * 2004-11-05 2006-06-15 Maruishi Pharmaceutical Co Ltd インスリン様成長因子−１分泌促進剤
US7282224B1 (en) 2006-06-09 2007-10-16 Guthy-Renker Corporation Pain relief composition
US20080107747A1 (en) * 2006-10-23 2008-05-08 Roederer Joy E Pain relief composition
WO2008075615A1 (en) * 2006-12-21 2008-06-26 Semiconductor Energy Laboratory Co., Ltd. Light-emitting element and light-emitting device
AU2008260774B2 (en) * 2007-06-08 2011-01-06 Samyang Biopharmaceuticals Corporation Matrix-type transdermal drug delivery system and preparation method thereof
RU2010108361A (ru) * 2010-03-09 2011-09-20 Гаврилова Эмилия Евгеньевна (RU) Набор лечебных средств
KR101857827B1 (ko) * 2010-06-09 2018-05-14 카오카부시키가이샤 수증기 발생 온열구
CN108473484B (zh) 2015-10-01 2021-06-29 弗门尼舍公司 可用作trpm8调节剂的化合物
JP7412870B2 (ja) * 2017-06-27 2024-01-15 小林製薬株式会社 外用組成物
JP7412871B2 (ja) * 2017-06-27 2024-01-15 小林製薬株式会社 外用組成物
EA031658B1 (ru) * 2017-06-30 2019-02-28 Акционерное Общество "Верофарм" Антицеллюлитный косметический комплекс
CA3030489A1 (en) * 2018-01-19 2019-07-19 Kwang Hyun Park Composition for controlling secretion of prostasomes and use thereof

Citations (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4387107A (en) * 1979-07-25 1983-06-07 Dermik Laboratories, Inc. Stable benzoyl peroxide composition
US4424205A (en) * 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4493848A (en) * 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4599379A (en) * 1984-01-17 1986-07-08 Allied Colloids Ltd. Process for the production of polymers and aqueous solutions thereof
US4628078A (en) * 1984-06-12 1986-12-09 Allied Colloids Ltd. Acrylamide-dialkylaminoacrylate-dialkylaminomethacrylate cationic polyelectrolytes and their production
US4812446A (en) * 1984-01-16 1989-03-14 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4835206A (en) * 1986-10-01 1989-05-30 Allied Colloids, Ltd. Water soluble polymeric compositions
US4849484A (en) * 1986-09-22 1989-07-18 Allied Colloids, Ltd. Polymeric particles, their manufacture and uses
US4911933A (en) * 1985-05-29 1990-03-27 Eye Research Institute Of Retina Foundation Non-toxic opthalmic preparations
US5100660A (en) * 1989-04-21 1992-03-31 Allied Colloids Limited Thickened acidic aqueous compositions using cross-linked dialkylaminoacrylic microparticles
US5288814A (en) * 1992-08-26 1994-02-22 The B. F. Goodrich Company Easy to disperse polycarboxylic acid thickeners
US5290816A (en) * 1988-10-24 1994-03-01 The United States Of America As Represented By The Secretary Of Health And Human Services Composition of resiniferatoxin and analogues thereof to cause sensory afferent C-Fiber and thermoregulatory desensitization
US5468814A (en) * 1992-10-30 1995-11-21 Research Corporation Technologies, Inc. Polymers having oxidic functionality and derivatives thereof
US5523017A (en) * 1991-10-07 1996-06-04 Nephin Solid cleansing bar
US5698191A (en) * 1996-01-30 1997-12-16 Nouveau Technologies, Inc. Non-lethal bio-repellent compositions
US5747052A (en) * 1995-06-09 1998-05-05 Anthony Rizzo Aqueous composition to neutralize the irritating effect of capsaicin on eyes, skin and mucous membranes
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
US5856361A (en) * 1996-04-23 1999-01-05 Medical Merchandising, Inc. Pain reliever and method of use
US5910512A (en) * 1994-04-18 1999-06-08 Healthline Laboratories, Inc. Topical analgesic using water soluble capsaicin
US5922331A (en) * 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
US5958436A (en) * 1995-12-21 1999-09-28 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5962532A (en) * 1997-03-13 1999-10-05 Campbell; James N. Therapeutic method with capsaicin and capsaicin analogues
US5994407A (en) * 1999-06-16 1999-11-30 Cuilty-Siller; Carlos Procedure to prepare a solution with capsaicin
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
US6015763A (en) * 1998-02-17 2000-01-18 Dotolo Research Corp. Cleaner impregnated towel
US6114290A (en) * 1997-11-07 2000-09-05 Lever Brothers Company, Division Of Conopco, Inc. Detergent composition
US6113892A (en) * 1997-12-23 2000-09-05 Helene Curtis, Inc. Compositions for cleansing, conditioning and moisturizing hair and skin
US6133212A (en) * 1995-05-27 2000-10-17 The Procter & Gamble Company Cleansing compositions
US6203804B1 (en) * 1997-10-28 2001-03-20 Kao Corporation External skin-care composition
US6239180B1 (en) * 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
US6248788B1 (en) * 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
US6277385B1 (en) * 1992-06-17 2001-08-21 The Procter & Gamble Company Cooling compositions with reduced stinging
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6403589B1 (en) * 1997-06-16 2002-06-11 Janssen Pharmaceutica N.V. Method of treating pain with draflazine-analogues
US6428772B1 (en) * 2001-06-25 2002-08-06 Blistex Inc. Acne treatment composition with cooling effect
US6569463B2 (en) * 1999-11-23 2003-05-27 Lipocine, Inc. Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions
US6593370B2 (en) * 1998-11-13 2003-07-15 Maruishi Pharmaceutical Co., Ltd. Topical capsaicin preparation
US6641825B2 (en) * 2000-03-01 2003-11-04 Henkel Kommanditgesellschaft Auf Aktien Skin cleansing gel having a heating effect
US20040180081A1 (en) * 2002-09-05 2004-09-16 Angel Arturo J. Compositions and kits for the removal of irritating compounds from bodily surfaces
US7074747B1 (en) * 1999-07-01 2006-07-11 Johnson & Johnson Consumer Companies, Inc. Cleansing compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239781A (en) * 1979-05-03 1980-12-16 Roy Edwards Method for treating skin ailments
US4303066A (en) * 1979-06-28 1981-12-01 National Patent Development Corporation Burn dressing
GB2075837B (en) * 1980-05-14 1984-03-14 Hisamitsu Pharmaceutical Co Topical pharmaceutical gel containing anti-inflammatory analgesic agents
GB8531118D0 (en) 1985-12-18 1986-01-29 Allied Colloids Ltd Copolymers
US5202118A (en) * 1987-12-18 1993-04-13 Immunex Corporation Method for promoting wound healing using IL-1
CA2063576C (en) * 1989-06-07 1994-01-25 Gail S. Bazzano Slow release vehicles for minimizing skin irritancy of topical compositions
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
FR2721213B1 (fr) 1994-06-15 1996-09-13 Pf Medicament Procédé de préparation d'un extrait de Capsicum, riche en capsaïcine et autres capsinoïdes.
US5624906A (en) * 1994-12-08 1997-04-29 Lever Brothers Company, Division Of Conopco, Inc. Oral hygiene compositions comprising heteroatom containing alkyl aldonamide compounds
US5703026A (en) * 1995-06-01 1997-12-30 The Procter & Gamble Company Skin cleansing bar soap compositions comprising particles of absorbent gellant materials
JP2000191510A (ja) 1998-12-28 2000-07-11 Kao Corp 皮膚洗浄剤組成物
WO2001001949A1 (en) * 1999-07-01 2001-01-11 Johnson And Johnson Consumer Companies, Inc. Cleansing compositions
HU225734B1 (en) * 1999-07-28 2007-07-30 Zoltan Dardai Multilayer plaster for introducing peptidaceous pharmacons in living organisms and process for producing thereof
US6342470B1 (en) * 2000-04-26 2002-01-29 Unilever Home & Personal Care Usa Bar comprising soap, fatty acid, polyalkylene glycol and protic acid salts in critical ratios and providing enhanced skin care benefits
US6774100B2 (en) * 2000-12-06 2004-08-10 Imaginative Research Associates, Inc. Anhydrous creams, lotions and gels
US20030235549A1 (en) * 2001-05-01 2003-12-25 Parminder Singh Hydrogel compositions demonstrating phase separation on contact with aqueous media
US6465022B1 (en) 2001-06-19 2002-10-15 New Mexico Tech Research Foundation Method of providing an essential oil extract of capsicum, and the extract
JP3881871B2 (ja) * 2001-11-13 2007-02-14 三菱重工業株式会社 ガスタービンの燃料制御方法、及びそれに供する制御装置
US20040131560A1 (en) * 2002-10-04 2004-07-08 The Procter & Gamble Company Oral compositions and use thereof
WO2005027642A1 (en) 2003-09-25 2005-03-31 Darren Wayne Eade Repellent preparations
US20060018845A1 (en) * 2004-07-23 2006-01-26 Edelstein Janette S Tooth whitening
DE102011077796A1 (de) 2011-06-20 2012-12-20 Voith Patent Gmbh Verfahren und System zur Wärmerückgewinnung für eine Trockenpartie einer Maschine zur Herstellung einer Materialbahn

Patent Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4387107A (en) * 1979-07-25 1983-06-07 Dermik Laboratories, Inc. Stable benzoyl peroxide composition
US4424205A (en) * 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4493848A (en) * 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
US4812446A (en) * 1984-01-16 1989-03-14 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4599379A (en) * 1984-01-17 1986-07-08 Allied Colloids Ltd. Process for the production of polymers and aqueous solutions thereof
US4628078A (en) * 1984-06-12 1986-12-09 Allied Colloids Ltd. Acrylamide-dialkylaminoacrylate-dialkylaminomethacrylate cationic polyelectrolytes and their production
US4911933A (en) * 1985-05-29 1990-03-27 Eye Research Institute Of Retina Foundation Non-toxic opthalmic preparations
US4849484A (en) * 1986-09-22 1989-07-18 Allied Colloids, Ltd. Polymeric particles, their manufacture and uses
US4835206A (en) * 1986-10-01 1989-05-30 Allied Colloids, Ltd. Water soluble polymeric compositions
US5290816A (en) * 1988-10-24 1994-03-01 The United States Of America As Represented By The Secretary Of Health And Human Services Composition of resiniferatoxin and analogues thereof to cause sensory afferent C-Fiber and thermoregulatory desensitization
US5100660A (en) * 1989-04-21 1992-03-31 Allied Colloids Limited Thickened acidic aqueous compositions using cross-linked dialkylaminoacrylic microparticles
US5523017A (en) * 1991-10-07 1996-06-04 Nephin Solid cleansing bar
US6277385B1 (en) * 1992-06-17 2001-08-21 The Procter & Gamble Company Cooling compositions with reduced stinging
US5288814A (en) * 1992-08-26 1994-02-22 The B. F. Goodrich Company Easy to disperse polycarboxylic acid thickeners
US5468814A (en) * 1992-10-30 1995-11-21 Research Corporation Technologies, Inc. Polymers having oxidic functionality and derivatives thereof
US5910512A (en) * 1994-04-18 1999-06-08 Healthline Laboratories, Inc. Topical analgesic using water soluble capsaicin
US6133212A (en) * 1995-05-27 2000-10-17 The Procter & Gamble Company Cleansing compositions
US5747052A (en) * 1995-06-09 1998-05-05 Anthony Rizzo Aqueous composition to neutralize the irritating effect of capsaicin on eyes, skin and mucous membranes
US20010002406A1 (en) * 1995-11-08 2001-05-31 Robbins Wendye R. Transdermal therapeutic device and method with capsaicin and capsaicin analogs
US6239180B1 (en) * 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
US5958436A (en) * 1995-12-21 1999-09-28 Cosmederm Technologies Formulations and methods for reducing skin irritation
US5698191A (en) * 1996-01-30 1997-12-16 Nouveau Technologies, Inc. Non-lethal bio-repellent compositions
US5856361A (en) * 1996-04-23 1999-01-05 Medical Merchandising, Inc. Pain reliever and method of use
US6248788B1 (en) * 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
US5962532A (en) * 1997-03-13 1999-10-05 Campbell; James N. Therapeutic method with capsaicin and capsaicin analogues
US5922331A (en) * 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
US5827886A (en) * 1997-05-07 1998-10-27 Thione International, Inc. Composition for relief of arthritis-induced symptoms
US6403589B1 (en) * 1997-06-16 2002-06-11 Janssen Pharmaceutica N.V. Method of treating pain with draflazine-analogues
US6203804B1 (en) * 1997-10-28 2001-03-20 Kao Corporation External skin-care composition
US6114290A (en) * 1997-11-07 2000-09-05 Lever Brothers Company, Division Of Conopco, Inc. Detergent composition
US6113892A (en) * 1997-12-23 2000-09-05 Helene Curtis, Inc. Compositions for cleansing, conditioning and moisturizing hair and skin
US6015763A (en) * 1998-02-17 2000-01-18 Dotolo Research Corp. Cleaner impregnated towel
US6013270A (en) * 1998-04-20 2000-01-11 The Procter & Gamble Company Skin care kit
US6593370B2 (en) * 1998-11-13 2003-07-15 Maruishi Pharmaceutical Co., Ltd. Topical capsaicin preparation
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US5994407A (en) * 1999-06-16 1999-11-30 Cuilty-Siller; Carlos Procedure to prepare a solution with capsaicin
US7074747B1 (en) * 1999-07-01 2006-07-11 Johnson & Johnson Consumer Companies, Inc. Cleansing compositions
US6569463B2 (en) * 1999-11-23 2003-05-27 Lipocine, Inc. Solid carriers for improved delivery of hydrophobic active ingredients in pharmaceutical compositions
US6641825B2 (en) * 2000-03-01 2003-11-04 Henkel Kommanditgesellschaft Auf Aktien Skin cleansing gel having a heating effect
US6428772B1 (en) * 2001-06-25 2002-08-06 Blistex Inc. Acne treatment composition with cooling effect
US20040180081A1 (en) * 2002-09-05 2004-09-16 Angel Arturo J. Compositions and kits for the removal of irritating compounds from bodily surfaces

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11534388B2 (en) 2002-09-05 2022-12-27 Averitas Pharma Inc. Compositions and kits for the removal of irritating compounds from bodily surfaces
US20060204564A1 (en) * 2002-09-05 2006-09-14 Angel Arturo J Compositions and kits for the removal of irritating compounds from bodily surfaces
US20060204563A1 (en) * 2002-09-05 2006-09-14 Angel Arturo J Compositions and kits for the removal of irritating compounds from bodily surfaces
US10869827B2 (en) 2002-09-05 2020-12-22 Averitas Pharma Inc. Compositions and kits for the removal of irritating compounds from bodily surfaces
US10463598B2 (en) 2002-09-05 2019-11-05 Averitas Pharma Inc. Compositions and kits for the removal of irritating compounds from bodily surfaces
US8889113B2 (en) 2002-09-05 2014-11-18 Acorda Therapeutics, Inc. Compositions and kits for the removal of irritating compounds from bodily surfaces
US8263059B2 (en) 2002-09-05 2012-09-11 Neurogesx, Inc. Compositions and kits for the removal of irritating compounds from bodily surfaces
US20100269858A1 (en) * 2002-09-05 2010-10-28 Neurogesx, Inc. Compositions and kits for the removal of irritating compounds from bodily surfaces
US20080064711A1 (en) * 2002-11-21 2008-03-13 J.P.M.E.D. Ltd. Composition for treating oral cavity and Mucousal infections
US8367733B2 (en) * 2002-12-18 2013-02-05 Vallinex, Inc. Infiltration of capsaicin into surgical sites and open wounds
US20060269628A1 (en) * 2002-12-18 2006-11-30 Algorx Infiltration of capsaicin into surgical sites and open wounds
US8420600B2 (en) * 2002-12-18 2013-04-16 Vallinex, Inc. Injectable capsaicin
US20070036876A1 (en) * 2002-12-18 2007-02-15 Algorx Injectable capsaicin
US20070293703A1 (en) * 2003-04-08 2007-12-20 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
US20060100287A1 (en) * 2004-11-05 2006-05-11 Kenji Okajima Insulin-like growth factor-1 secretagogue
US20060148903A1 (en) * 2004-11-24 2006-07-06 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
US7771760B2 (en) 2005-04-01 2010-08-10 Neurogesx, Inc. Oils of capsaicinoids and methods of making and using the same
US20060233901A1 (en) * 2005-04-01 2006-10-19 Jamieson Gene C Oils of capsaicinoids and methods of making and using the same
US20070224155A1 (en) * 2006-03-21 2007-09-27 Access Business Group International, Llc Cleansing compositions and methods of reducing skin irritation
US8057830B2 (en) * 2006-03-21 2011-11-15 Access Business Group International Llc Cleansing compositions and methods of reducing skin irritation
WO2008103180A1 (en) 2007-02-23 2008-08-28 Hill's Pet Nutrition, Inc. Compositions and methods for preventing or treating obesity in animals
US20100234470A1 (en) * 2008-09-12 2010-09-16 Anesiva, Inc. Instillation Administration of Capsaicinoids for the Treatment of Pain
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
US20180296497A1 (en) * 2014-10-31 2018-10-18 Avent, Inc. Method and Articles for Inhibiting Bladder Contractions

Also Published As

Publication number Publication date
ES2687970T3 (es) 2018-10-30
CA2497771C (en) 2015-11-03
LT1539124T (lt) 2018-11-12
HUE042241T2 (hu) 2019-06-28
PT1539124T (pt) 2018-10-22
SI1539124T1 (sl) 2018-12-31
EP1539124A4 (en) 2011-02-23
CA2903031A1 (en) 2004-03-18
JP2006502166A (ja) 2006-01-19
US8889113B2 (en) 2014-11-18
WO2004021990A3 (en) 2004-08-26
US10463598B2 (en) 2019-11-05
US20060204564A1 (en) 2006-09-14
EA012367B1 (ru) 2009-10-30
US10869827B2 (en) 2020-12-22
US11534388B2 (en) 2022-12-27
US20150104498A1 (en) 2015-04-16
US20210205205A1 (en) 2021-07-08
US20170312214A1 (en) 2017-11-02
JP2009084289A (ja) 2009-04-23
EP1539124B1 (en) 2018-07-18
CA2497771A1 (en) 2004-03-18
US20100269858A1 (en) 2010-10-28
EP1539124A2 (en) 2005-06-15
JP4279254B2 (ja) 2009-06-17
DK1539124T3 (en) 2018-10-08
EA200500442A1 (ru) 2005-10-27
US20200085718A1 (en) 2020-03-19
WO2004021990A2 (en) 2004-03-18
CA2903031C (en) 2019-04-16
US8263059B2 (en) 2012-09-11
CY1120926T1 (el) 2019-12-11
US20040180081A1 (en) 2004-09-16
US20060204563A1 (en) 2006-09-14
US20120323258A1 (en) 2012-12-20
AU2003270325A8 (en) 2004-03-29
US9549893B2 (en) 2017-01-24
MXPA05002440A (es) 2005-11-17
AU2003270325A1 (en) 2004-03-29

Similar Documents

Publication Publication Date Title
US11534388B2 (en) Compositions and kits for the removal of irritating compounds from bodily surfaces
RU2653488C2 (ru) Композиция для местного лечения ран
FI78235B (fi) Foerfarande foer framstaellning av en topisk anti-inflammatorisk komposition i gelsalvaform.
KR20210150462A (ko) 대상체의 피부 상의 미생물총에 영향을 미치는 키토산을 포함하는 액체 조성물
RU2342923C1 (ru) Дезинфицирующее антисептическое средство для обработки рук с увлажняющим эффектом (варианты)
JP2003055138A (ja) プロポリス含有シート状化粧料
CN118593392A (zh) 一种男士清洁抗菌湿巾
KR20240011720A (ko) 체강 내 적용을 위한 칸나비디올 함유 조성물
TR2021018637A2 (tr) Uzun etki̇li̇ lokal anestezi̇k krem, jel ve sprey formülasyonu
CN117715521A (zh) 感觉改善的基于醇的擦入式手部消毒剂组合物
RU2450807C1 (ru) Стабилизированный фармацевтический состав с противогрибковым действием
WO2017105207A1 (es) Composicion farmaceutica para tratamiento de heridas, quemaduras y ulceras cutaneas

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEUROGESX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DOW PHARMACEUTICAL SCIENCES;REEL/FRAME:014723/0780

Effective date: 20040116

Owner name: DOW PHARMACEUTICAL SCIENCES, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANGEL, ARTURO J.;LITLE, LARRY W.;REEL/FRAME:014723/0789

Effective date: 20031223

Owner name: NEUROGESX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WILCOX, ALLAN L.;REEL/FRAME:014723/0837

Effective date: 20031212

AS Assignment

Owner name: NEUROGESX, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANGEL, ARTURO J.;LITLE, LARRY W.;BLEY, KEITH R.;AND OTHERS;REEL/FRAME:017705/0131;SIGNING DATES FROM 20031212 TO 20060523

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: ACORDA THERAPEUTICS, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NEUROGESX, INC.;REEL/FRAME:047829/0299

Effective date: 20130708